Nov 28, 2023 / 09:00PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
All right. Good afternoon, everybody. Thanks so much for joining us. Matt O'Brien. I cover medical technology here at Piper Sandler. I'm very fortunate to have Integra with us here. From the company is Jan, who is the CEO, and then a couple of folks from IR are out in the audience. So thanks so much for coming out. I really do appreciate it.
Jan De Witte - Integra LifeSciences Holdings Corporation - President, CEO & Director
Great to be here, Matt.
Questions and Answers:
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research AnalystExcellent. So maybe start a little bit with Q3. It was a little bit better than you expected, a little more stable than I think a lot of folks, I guess, generally, were expecting for Medtech. So what did you see in Q3? And then the early days of Q4 that, prior to the earnings call, what were you seeing